SiBionics announced today that it received CE mark approval in Europe for its GS1 continuous glucose monitoring (CGM) system. The company designed its CGM system to provide healthcare providers and patients with data necessary for maintaining glucose control. It offers 14 days of calibration-free continuous glucose monitoring and can transmit data to monitoring devices or […]
Patient Monitoring
Dexcom stock rises after hours on raised 2023 guidance, $500M share repurchase program
Dexcom (Nasdaq:DXCM) shares got a massive boost on third-quarter results that came in well ahead of the consensus forecast. The San Diego-based continuous glucose monitor (CGM) maker also announced a $500 million share repurchase program in conjunction with its third-quarter results. The repurchase program follows a $1 billion senior convertible note offering this year, plus […]
How Abbott developed an accessible, affordable CGM — the FreeStyle Libre system
According to Abbott Diabetes DVP, Technical Operations, Marc Taub, one in nine people in the U.S. live with diabetes. Speaking at DeviceTalks West in Santa Clara, California, he said that means everyone in the room at the time knows someone with diabetes. The condition requires constant attention and management, something Taub and Abbott aim to alleviate. […]
Tandem Diabetes Care has positive artificial pancreas data
Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology. Diabetes Technology & Therapeutics made data available from the Control-IQ Observational (CLIO) study. It’s the largest prospective study of the Control-IQ advanced hybrid closed-loop technology to date. Twelve-month results showed, among other results, lower adverse events for type […]
Signos raises $20M for AI-powered CGM tech with backing from Google Ventures, Dexcom Ventures
Signos announced that it raised $20 million in a Series B round to support its AI-powered continuous glucose monitor (CGM) technology. San Francisco-based Signos develops a comprehensive metabolic health platform. It includes a proprietary AI engine with a CGM to provide real-time data and recommendations for weight management. Signos aims for its metabolic-led solution to […]
FDA clears iPhone app for the Insulet Omnipod 5
Insulet (Nasdaq:PODD) announced today that the FDA granted 510(k) clearance for its Omnipod 5 App for iPhone. Clearance makes Insulet the only company offering a tubeless, automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone. The company first launched the system, compatible with Android devices, in August 2022. Insulet […]
The challenges Insulet overcame to deliver the Omnipod 5 automated insulin delivery system
Insulet (Nasdaq:PODD) had to clear a series of hurdles to bring the Omnipod 5 automated insulin delivery system to those who need it. Speaking at DeviceTalks West in Santa Clara, California on Oct. 18, Mark Field, Insulet’s CTO, explained the trials and tribulations. He presented in a session titled “Overcoming Challenges to Develop the Omnipod […]
How automated insulin delivery integration drives Dexcom CGM forward
Dexcom (Nasdaq:DXCM) is a company known as one of the market leaders in continuous glucose monitoring (CGM) technology. CGMs are a key system for people with diabetes to manage their condition. But, Dexcom has worked to ensure that its CGM technology goes beyond its standalone capabilities. The Dexcom G6, the company’s previous-generation CGM, integrates with […]
How the new Medtronic CGM-insulin pen combo simplifies diabetes management
Medtronic (NYSE:MDT) named its next-generation “Simplera” continuous glucose monitor (CGM) as a nod to its simplicity. The company, which just initiated the system’s launch in Europe following CE mark approval, is exceedingly optimistic about the technology. Medtronic’s all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Its […]
Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes
Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]